Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666991 | 0.98 | BBOX1 (0.40) | LMNAKMT2ABBOX1KDM4EAPOBEC3A | |
| SCHEMBL2831120 | 0.91 | LMNA (0.41) | LMNAKMT2ABBOX1KDM4EAPOBEC3A | |
| SCHEMBL1881492 | 0.91 | LMNA (0.41) | LMNAKMT2ABBOX1KDM4EAPOBEC3A | |
| SCHEMBL1534010 | 0.86 | KDM4E (0.36) | LMNAKMT2ABBOX1KDM4E | |
| Cyanamide SCHEMBL206467 | 0.85 | BBOX1 (0.41) | LMNAKMT2ABBOX1KDM4EAPOBEC3A | |
| SCHEMBL205619 | 0.84 | BBOX1 (0.50) | LMNAKMT2ABBOX1KDM4EAPOBEC3A | |
| SCHEMBL320814 | 0.84 | BBOX1 (0.50) | LMNAKMT2ABBOX1KDM4EAPOBEC3A | |
| Cyanamide SCHEMBL666990 | 0.82 | BBOX1 (0.42) | LMNAKMT2ABBOX1KDM4EAPOBEC3A | |
| Thiocyanic Acid SCHEMBL613342 | 0.82 | BBOX1 (0.42) | LMNAKMT2ABBOX1KDM4EAPOBEC3A | |
| SCHEMBL30212825 | 0.82 | BBOX1 (0.45) | LMNAKMT2ABBOX1KDM4EAPOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102647-B2 | Method for preparing lactide using an ionic solvent | HYUNDAI MOTOR COMPANY (KR) | 2015-08-11 | — | — | US | claimed |
| US-20140187798-A1 | METHOD FOR PREPARING LACTIDE USING AN IONIC SOLVENT | HYUNDAI MOTOR COMPANY (KR) | 2014-07-03 | — | — | US | claimed |
| EP-2162435-B1 | Ionic liquids as electrolytes | INVISTA TECH SARL (CH) | 2013-09-04 | — | — | EP | claimed |
| US-8088917-B2 | Ionic liquids | INVISTA NORTH AMERICA S.A R.L. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2162435-A1 | IONIC LIQUIDS AS ELECTROLYTES | Invista Technologies S.A.R.L. (US) | 2010-03-17 | — | — | EP | claimed |
| WO-2008150842-A1 | IONIC LIQUIDS AS ELECTROLYTES | INVISTA TECHNOLOGIES S.A.R.L. (US) | 2008-12-11 | — | — | WO | claimed |
| US-20080296531-A1 | IONIC LIQUIDS | INVISTA NORTH AMERICA S.A R.L. (US) | 2008-12-04 | — | — | US | claimed |
| US-9102647-B2 | Method for preparing lactide using an ionic solvent | HYUNDAI MOTOR COMPANY (KR) | 2015-08-11 | — | — | US | disclosed |
| US-20140187798-A1 | METHOD FOR PREPARING LACTIDE USING AN IONIC SOLVENT | HYUNDAI MOTOR COMPANY (KR) | 2014-07-03 | — | — | US | disclosed |
| EP-2162435-B1 | Ionic liquids as electrolytes | INVISTA TECH SARL (CH) | 2013-09-04 | — | — | EP | disclosed |
| EP-2456807-B1 | SYNTHESIS METHOD USING IONIC LIQUIDS | INVISTA TECH SARL (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120190844-A1 | IONIC LIQUIDS | INVISTA NORTH AMERICA S.A R.L. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2456807-A2 | SYNTHESIS METHOD USING IONIC LIQUIDS | Invista Technologies S.A R.L. (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-8088917-B2 | Ionic liquids | INVISTA NORTH AMERICA S.A R.L. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011010116-A2 | SYNTHESIS METHOD USING IONIC LIQUIDS | INVISTA TECHNOLOGIES S.À.R.L. (CH) | 2011-01-27 | — | — | WO | disclosed |
| EP-2162435-A1 | IONIC LIQUIDS AS ELECTROLYTES | Invista Technologies S.A.R.L. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150842-A1 | IONIC LIQUIDS AS ELECTROLYTES | INVISTA TECHNOLOGIES S.A.R.L. (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080296531-A1 | IONIC LIQUIDS | INVISTA NORTH AMERICA S.A R.L. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190844-A1 | IONIC LIQUIDS | INF2, H1-2, H1-0 | LMNA 223/4885KMT2A 2972/4885BBOX1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.